CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 136 enrolled
Drug / intervention
Indacaterol +1 moredrug
Likely dose
Indacaterol 150µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01778062
NCT01778062Phase 3Completed
CompareCT.gov

A Phase Ⅲb, Multicenter, Double-blind, Randomized, Controlled Trial, to Assess the Efficacy and Safety of Indacaterol (150㎍ o.d.) vs. Placebo, in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Novartis Pharmaceuticals·interventional·Posted Jan 29, 2013·Updated Oct 23, 2015

In Brief

A Phase 3 clinical trial evaluating Indacaterol and Control for Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis. Completed, enrolled 136 participants across 13 sites.

Detailed Summary

This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
CountriesSouth Korea
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 29, 2013
Enrollment StartFeb 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.4 years ago

Interventions

Indacateroldrug

Indacaterol 150µg once daily oral inhalation

Controldrug

Placebo once daily oral inhalation